CNR1 and cancer: This gives quite a clear view of the anticancer activity, though it has to be kept in mind that there is a possibility that the SAR might change when tested on different cancer cell lines, and of course this SAR is irrelevant for other activities (binding to CB1/CB2, PPARγ agonism or other possible targets).